

Product datasheet for **KN504093**

Cyp1a1 Mouse Gene Knockout Kit (CRISPR)

Product data:

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 linear donor
Donor DNA:	EF1a-GFP-P2A-Puro
Symbol:	Cyp1a1
Locus ID:	13076



[View online »](#)

Components:
KN504093G1, Cyp1a1 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002)

KN504093G2, Cyp1a1 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002)

KN504093D, Linear donor DNA containing LoxP-EF1a-tGFP-P2A-Puro-LoxP:

The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.

LoxP-EF1a-tGFP-P2A-Puro-LoxP (2739 bp)

```

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA
CATCGCCAC AGTCCCCGAG AAGTTGGGG GAGGGGTCGG CAATTGAACC GGTGCCTAGA GAAGGTGGCG
CGGGGTAAC TGGGAAAGTG ATGTCGTGTA CTGGCTCCGC CTTTTCCCG AGGGTGGGG AGAACCGTAT
ATAAGTCAG TAGTCGCCG GAACGTTCTT TTTCCGAACG GGTTCGCCG CAGAACACAG GTAAGTGCCG
TGTGTGGTTC CCGCGGGCCT GGCCTCTTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTTCCACCTG
GCTGCAGTAC GTGATTCTTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGGG AGAGTTCGAG GCCTTGCGCT
TAAGGAGCCC CTTCGCCTCG TGCTTGAGTT GAGGCCTGGC CTGGGCGCTG GGGCCCGCG GTGCGAATCT
GGTGGCACCT TCGCGCCTGT CTCGCTGCTT TCGATAAGTC TCTAGCCATT TAAAATTTT GATGACCTGC
TGCAGCGCTT TTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTTTCGTT
TTTGGGGCCG CGGGCGGCGA CGGGGCCCGT GCGTCCCAGC GCACATGTTC GGCGAGGCGG GGCCTGCGAG
CGCGGCCACC GAGAATCGGA CGGGGGTAGT CCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC
GCCGTGTATC GCCCGCCCT GGGCGGCAAG GCTGGCCCGG TCGGCACCAG TTGCGTGAGC GGAAAGATGG
CCGCTTCCCG GCCCTGTGC AGGGAGCTCA AAATGGAGGA CGCGGCGCTC GGGAGAGCGG GCGGGTGAGT
CACCCACACA AAGGAAAAGG GCCTTCCCGT CCTCAGCCGT CGCTTCATGT GACTCCACGG AGTACCGGGC
GCCCTCCAGG CACCTCGATT AGTTCTCGAG CTTTTGGAGT ACGTCGTCTT TAGTTGGGG GGAGGGGTTT
TATGCGATGG AGTTTCCCA CACTGAGTGG GTGAGACTG AAGTTAGGCC AGCTTGGCAG TTGATGTAAT
TCTCCTTGGG ATTTGCCCTT TTTGAGTTTG GATCTTGGTT CATTCTCAAG CCTCAGACAG TGGTTCAAAG
TTTTTTCTT CCATTTCAAG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCCAT GGAGATCGAG
TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGGC ACCCCCGAGC
AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCTACC TGCTGAGCCA
CGTGATGGG TACGGCTTCT ACCACTTCGG CACCTACCCC AGCGGCTACG AGAACCCCTT CCTGCACGCC
ATCAACAACG GCGGCTACAC CAACACCCG ATCGAGAAGT ACGAGGACGG CGGCGTGCTG CACGTGAGCT
TCAGCTACCG CTACGAGGCC GGCCGCGTGA TCGGCGACTT CAAGGTGATG GGCACCGGCT TCCCGGAGGA
CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGCGGAT
AACGATCTGG ATGGCAGCTT CACCCGACC TTCAGCCTGC GCGACGGCGG CTACTACAGC TCCGTGGTGG
ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCA TGTTCCCTT
CCGCCCGTG GAGGAGGATC ACAGCAACAC CGAGTGGGG ATCGTGGAGT ACCAGCACGC CTTCAAGACC
CCGGATGCAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTAACCTCAG CCTGCTGAAG CAGGCTGGAG
ACGTGGAGGA GAACCTGGA CCTATGACCG AGTACAAGCC CACGGTGC GCCTGCCACC GCGACGACGT
CCCCAGGGCC GTACGCACCC TCGCCGCCG GTTCGCCGAC TACCCGCCA CGGCCACAC CGTCGATCCG
GACCGCCACA TCGAGCGGGT CACCGAGCTG CAAGAATCT TCCTCACGCG CGTCGGGCTC GACATCGGCA
AGGTGTGGGT CGCGGACGAC GGCGCCCGG TGGCGGTCTG GACCACGCCG GAGAGCGTGC AAGCGGGGGC
GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCGGGC TGGCCCGCA GCAACAGATG
GAAGGCCTCC TGGCGCCGCA CCGGCCAAG GAGCCCGCT GTTCTCTGGC CACCCTCGGC GTCTCGCCG
ACCACCAGGG CAAGGTCTG GGCAGCGCG TCGTGTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGT
GCCCGCTTC CTGGAGACCT CCGCGCCCG CAACCTCCC TTCTACGAGC GGCTCGGCT CACCGTCACC
GCCGACGTC AGGTGCCGA AGGACCGCG ACCTGGTGA TGACCCGCA GCCCGGTGCC TGAACTTGT
TTATTGCAGC TTATAATGGT TACAAATAA GCAATAGCAT CACAAATTC ACAAATAAG CATTTTTTTC
ACTGCATTCT AGTTGTGGT TGTCCAACT CATCAATGA TCTTAATAAC TTCGTATAAT GTATGCTATA CGAAGTTAT
    
```



Disclaimer: These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

RefSeq: [NM_001136059](#), [NM_009992](#)

UniProt ID: [P00184](#)

Synonyms: AHH; AHRR; CP11; Cyp1a2; P450-1

Summary: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds. Exhibits high catalytic activity for the formation of hydroxysteroids from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C15alpha and C16alpha positions. Displays different regioselectivities for polyunsaturated fatty acids (PUFA) hydroxylation. Catalyzes the epoxidation of double bonds of certain PUFA. Converts arachidonic acid toward epoxyeicosatrienoic acid (EET) regioisomers, 8,9-, 11,12-, and 14,15-EET, that function as lipid mediators in the vascular system. Displays an absolute stereoselectivity in the epoxidation of eicosapentaenoic acid (EPA) producing the 17(R),18(S) enantiomer. May play an important role in all-trans retinoic acid biosynthesis in extrahepatic tissues. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid. May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent).[UniProtKB/Swiss-Prot Function]

Product images:

